Hospital pharmacy teams make decisions every day that touch drug spend, supply chain stability, and 340B compliance simultaneously. Which National Drug Code (NDC) to buy, which supplier fills the order, and which site receives the drugs each carry financial and regulatory weight. The challenge is that the data supporting those decisions rarely lives in one place.
Wholesaler invoices, electronic health record (EHR) data, dispensing cabinet logs, and third-party administrator (TPA) claims each sit in separate systems. Pharmacy teams stitch them together manually to monitor costs, manage shortages, and validate 340B eligibility. With overall clinic and hospital drug spend projected to grow 11–13% in 2025 and pharmacy technician shortages limiting bandwidth for manual reconciliation, that approach is no longer sustainable.
Fortunately, when data sources are unified, the decisions they support improve across all three domains at once: drug spend is optimized with full contract and pricing context, shortage response is faster and more compliant, and 340B validation happens at the point of purchase rather than after the fact. The result is reduced risk and better financial performance, driven by the same data infrastructure.
The Data Fragmentation Problem Hospital Pharmacy Leaders Face
The scale of what pharmacy teams manage daily makes fragmentation a structural problem, not a staffing one. According to Bluesight’s 2025 Hospital Pharmacy Purchasing Trends Report:
- Hospitals manage 20,000+ NDCs and absorb 10,000+ weekly price updates
- 50% of purchasing teams source from 4 to 6 suppliers; 31% manage 12 or more
- 88% of hospitals report pharmacy technician shortages
Each additional supplier brings its own pricing terms, contract requirements, and compliance implications. When purchasing data, compliance data, and inventory data sit in separate systems, a lower-cost NDC from a secondary supplier may be ineligible for 340B pricing at a specific site with no one positioned to catch it. An invoice discrepancy that signals a contract misload gets logged as a one-time variance instead.
The downstream effect is audit exposure generated not by intentional misuse, but by data gaps that no single team has the visibility or bandwidth to close.
Why Purchasing Decisions Carry More Weight Than Most Teams Realize
Hospital pharmacy purchasing has always required operational precision. What has changed is the range of downstream consequences attached to each decision. As the 340B Drug Pricing Program (340B) has expanded to more covered entities, more contract pharmacies, and more transaction volume, each transaction now carries documentation and eligibility requirements that trace directly back to how and where a drug was purchased. Three areas concentrate that risk: 340B eligibility, rebate model uncertainty, and the Group Purchasing Organization (GPO) prohibition.
The 340B Stakes Are High and Getting Higher
340B covered entity purchases reached $81.4 billion in 2024, a 23% increase from 2023. The number of covered entity sites has more than tripled since 2012, surpassing 60,000 in 2024. HRSA audits a limited number of covered entities each year relative to that population, so the probability of selection in any given year is low. The consequences when a covered entity is selected, however, are significant.
HRSA audits of covered entities examine:
- Verification of site eligibility, including outpatient facility registration in the Office of Pharmacy Affairs Information System (OPAIS)
- Compliance with the GPO prohibition for Disproportionate Share Hospitals (DSHs), freestanding cancer hospitals, and children’s hospitals
- Prevention of diversion and duplicate discounts
- Purchasing documentation and the accuracy of procurement records
Non-compliance outcomes range from manufacturer repayment obligations to removal from the 340B program. HRSA posts finalized audit findings publicly, and incorrect OPAIS records, tied directly to site registration and purchasing documentation, are among the most common findings across recent fiscal years.
The GPO Prohibition: A Purchasing Decision With Compliance Consequences
Under HRSA program requirements, DSH hospitals, freestanding cancer hospitals, and children’s hospitals are prohibited from using a GPO for covered outpatient drugs. That restriction is enforced at the transaction level during HRSA audits.
- Untracked GPO purchases within 340B-eligible facilities are a direct audit finding risk.
- Managing the prohibition requires simultaneous visibility into both the purchasing pathway and the site’s eligibility status. In most health systems, those two data streams do not live in the same place.
- Covered entities must notify manufacturers and wholesalers of their 340B status and maintain auditable procurement records that demonstrate compliance with the GPO prohibition.
Without pharmacy inventory management systems that connect site eligibility to purchasing records, teams are left to catch GPO prohibition violations after the fact, often during audit prep rather than at the point of purchase. The same gap that creates 340B margin risk also creates audit risk.
What Unified Pharmacy Data Actually Enables
Unified data changes what is possible at the point of purchase, replenishment, and audit preparation. Three operational areas see the most direct impact.
- Pharmacy teams move from reconciling compliance gaps after transactions occur to preventing them at the moment of procurement.
- Compliance stakeholders gain continuous visibility rather than point-in-time audit snapshots.
Pharmacy Inventory Management That Accounts for Compliance
Effective pharmacy inventory management requires more than stock level visibility. It requires knowing which NDCs can be purchased through which pathways at which sites, and having the documentation to prove it.
When inventory data integrates with site eligibility and purchasing records, teams can identify 340B-eligible transactions in real time. That shifts inventory control hospital teams rely on from a reactive reconciliation exercise to a proactive compliance function.
Bluesight’s 340BCheck supports this by:
- Automating 100% transaction auditing rather than relying on sample-based review
- Matching records against OPAIS daily to surface discrepancies before they become audit findings
- Centralizing TPA claims, audit reports, and pharmacy service agreements in a single location for audit readiness
Pharmacy Purchasing Optimization Without Sacrificing Compliance
Pharmacy purchasing has traditionally focused on price: finding equivalent NDCs at lower cost, monitoring contracts, and catching invoice errors. Those are the right priorities. The risk is that price optimization disconnected from compliance context can generate new exposure.
Substituting an NDC may change 340B eligibility at a specific site. Sourcing from a secondary wholesaler during a shortage may route a purchase through a pathway that triggers a GPO prohibition violation. Catching those risks requires purchasing and compliance data to be visible together.
Bluesight’s CostCheck addresses both sides of that equation:
- Identifies alternative equivalent NDCs at lower cost, averaging up to $15,000 in savings per recommendation
- Monitors 100% of contracts and invoices, catching overlooked billing errors and mischarges that can exceed $1 million annually
- Surfaces pricing anomalies and contract outliers across primary and secondary wholesalers
- Integrates with 340BCheck so cost recommendations reflect eligibility and purchasing pathway context, not just unit price
Supply Chain Visibility That Reduces Shortage-Driven Risk
Drug shortages cost hospitals nearly $900 million annually in labor, and 75% of pharmacy leaders cite shortages as a top-three operational concern. The AHA’s 2024 Costs of Caring report found that drug shortages added as much as 20% to hospital drug budgets in 2023, the worst year for shortages in over a decade.
When shortages force teams outside primary supplier relationships, purchasing teams often lose visibility into whether secondary-market NDCs meet 340B purchasing pathway requirements. Compliance gaps emerge at the exact moment operational pressure peaks.
Predictive shortage tools close that window. Bluesight’s ShortageCheck flagged an acetaminophen shortage 64 days before the official notice, giving teams enough lead time to secure compliant supply through primary channels rather than reacting to a shortage by sourcing outside established purchasing pathways.
The Operational Case for a Unified Data Platform
When purchasing, inventory, and compliance data exist in separate systems, pharmacy leaders make decisions with incomplete information. Compliance teams audit those decisions after the fact, without the ability to prevent violations upstream. The sequencing is backwards.
A unified platform changes the order of operations. Compliance validation moves to the point of purchase. Inventory replenishment accounts for site eligibility before an order is placed. Audit documentation generates automatically rather than through manual record-pulling during audit prep.
Bluesight integrates data from wholesalers, EHRs, dispensing cabinets, TPA systems, and HR systems, giving pharmacy and compliance stakeholders a shared view of what was purchased, from which supplier, for which site, and whether it was 340B-eligible. That is the continuous internal auditing posture HRSA recommends, with documentation ready before an engagement letter arrives.
Fragmented and unified data environments produce meaningfully different outcomes across the compliance and cost functions pharmacy leaders manage every day:
| Function | Fragmented Data Environment | Unified Data Environment |
| 340B eligibility validation | Reconciled after purchase, often manually | Validated at the point of purchase in real time |
| GPO prohibition monitoring | Identified during audit prep or after a finding | Flagged at the transaction level before an order is placed |
| Invoice error detection | Caught inconsistently through manual review | Monitored across 100% of invoices automatically |
| Shortage response | Reactive sourcing from secondary markets, with compliance gaps | Predictive alerts up to 90 days ahead, supporting compliant sourcing |
| Audit readiness | Documentation assembled under time pressure | Continuously maintained and accessible on demand |
The Case for a Single Data Layer
Fragmented data does not just create compliance risk. It creates cost overruns that go undetected, shortage responses that generate purchasing workarounds, and 340B validation gaps that surface during audits rather than at the point of purchase. Those are three separate operational problems with one root cause.
Unified pharmacy data addresses all three from the same infrastructure. Drug spend decisions are made with full contract, pricing, and eligibility context. Shortage alerts arrive early enough to source through compliant channels. 340B transactions are validated continuously rather than reconciled after the fact. Bluesight’s connected platform spans pharmacy inventory management, purchasing optimization, 340B compliance, and drug shortage management under one vendor, with one data layer connecting them. To see how it works in practice, schedule a demo with the Bluesight team.